Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers

Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

What is claimed is: 
     
         1 . A method of treating a patient who has cancer, comprising administering to said patient activated T cells that kill cancer cells that present on the surface a peptide consisting of the amino acid sequence of FMNDRSFIL (SEQ ID NO: 25), wherein the cancer is small cell lung cancer (SCLC), colorectal cancer (CRC), breast cancer (BRCA), pancreatic cancer (PACA), squamous cell non-small cell lung cancer (NSCLCsquam), gastric cancer (GC), or gallbladder cancer (GBC). 
     
     
         2 . The method of  claim 1 , wherein the activated T cells are produced by transducing T cells with a T cell receptor (TCR) that binds the peptide in a complex with an MHC class I molecule on the surface of the cancer cells. 
     
     
         3 . The method of  claim 1 , wherein the cancer is SCLC. 
     
     
         4 . The method of  claim 1 , wherein the cancer is CRC. 
     
     
         5 . The method of  claim 1 , wherein the cancer is BRCA. 
     
     
         6 . The method of  claim 1 , wherein the cancer is PACA. 
     
     
         7 . The method of  claim 1 , wherein the cancer is NSCLCsquam. 
     
     
         8 . The method of  claim 1 , wherein the cancer is GC. 
     
     
         9 . The method of  claim 1 , wherein the cancer is GBC. 
     
     
         10 . The method of  claim 1 , further comprising administering to said patient at least one cytokine selected from Table 6 and/or at least one compound selected from an adjuvant, a chemotherapeutic agent, a natural product, a hormone, a hormone antagonist, an anti-angiogenesis agent, an anti-angiogenesis agent inhibitor, an apoptosis-inducing agent, and a chelator. 
     
     
         11 . A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient activated T cells that kill cancer cells that present on the surface a peptide consisting of the amino acid sequence of FMNDRSFIL (SEQ ID NO: 25), wherein the cancer is SCLC, CRC, BRCA, PACA, NSCLCsquam, GC, or GBC. 
     
     
         12 . The method of  claim 11 , wherein the activated T cells are produced by transducing T cells with a T cell receptor (TCR) that binds the peptide in a complex with an MHC class I molecule on the surface of the cancer cells. 
     
     
         13 . The method of  claim 11 , wherein the cancer is SCLC. 
     
     
         14 . The method of  claim 11 , wherein the cancer is CRC. 
     
     
         15 . The method of  claim 11 , wherein the cancer is BRCA. 
     
     
         16 . The method of  claim 11 , wherein the cancer is PACA. 
     
     
         17 . The method of  claim 11 , wherein the cancer is NSCLCsquam. 
     
     
         18 . The method of  claim 11 , wherein the cancer is GC. 
     
     
         19 . The method of  claim 11 , wherein the cancer is GBC. 
     
     
         20 . The method of  claim 11 , further comprising administering to said patient at least one cytokine selected from Table 6 and/or at least one compound selected from an adjuvant, a chemotherapeutic agent, a natural product, a hormone, a hormone antagonist, an anti-angiogenesis agent, an anti-angiogenesis agent inhibitor, an apoptosis-inducing agent, and a chelator.